Squamous cell carcinoma of the lung: lines of therapy

Cancer page →

3 standard-of-care settings across 3 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

Line	All comers
Early / localised	1
Advanced, first line	1
Third line and beyond	1

Early / localised

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Early stage	Treated as the parent's resectable and stage III pages describe.	Resectable stage I to III non-small-cell lung cancerUnresectable stage III non-small-cell lung cancer		-

Advanced, first line

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Metastatic, first line	Carboplatin with paclitaxel or nab-paclitaxel plus pembrolizumab (KEYNOTE-407); cemiplimab with chemotherapy or the parent's PD-L1-high pathway as alternatives.	KEYNOTE-407PembrolizumabCarboplatinPaclitaxel / nab-paclitaxelNab-paclitaxelCemiplimabPD-L1-high non-small-cell lung cancer without a driver mutation		98

Third line and beyond

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Metastatic, later lines	Docetaxel with or without ramucirumab; afatinib; biomarker-matched drugs through Lung-MAP.	DocetaxelRamucirumabAfatinibLung-MAP (SWOG S1400 and S1900)Lung-MAP S1400I: nivolumab with or without ipilimumab		86

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.